Prognostic value of AR mutation in primary African American prostate cancer

AR 突变在非裔美国人原发性前列腺癌中的预后价值

基本信息

  • 批准号:
    7989304
  • 负责人:
  • 金额:
    $ 19.98万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-07-01 至 2012-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Prostate cancer (PCa) incidence and mortality rate is higher in African American (AA) men than in Caucasian Americans (CAs). AA men with PCa also present with higher tumor volume, more advanced tumor stage, and higher Gleason grade. Prostate carcinogenesis and tumor progression are related strongly to the expression and activity of the androgen receptor (AR). Mutations and genomic amplification of AR also can increase AR expression and/or activity. In CAs, AR mutations are infrequent (<1%) in localized tumors, but occur at a higher frequency in advanced, metastatic, or hormone-refractory disease. In AAs, the prevalence of AR mutations and their prognostic significances in primary PCa are unknown. We discovered genomic amplification and somatic mutation of AR in a PCa cell line established by our laboratory from an AA patient with localized PCa. We analyzed a set of 91 radical prostatectomy samples (57 AAs and 34 CAs) in which we identified 8 AR mutations (7 somatic and 1 germline) in AA patients, but found no mutations in CA patients. These data led us to hypothesize that AR mutations in primary African Americans PCa is more frequent than expected and may contribute to disease aggressiveness or serve as a prognostic factor. Our Specific Aims are: Aim 1: Determine the prevalence of AR mutations in primary African Americans PCa. Exon-specific primers of the AR gene will be used to sequence genomic-DNA extracted from laser-captured cells of paraffin- embedded tissue sections of radical prostatectomy specimens in order to determine the prevalence of somatic AR mutations in 400 AA patients with primary untreated PCa, and compare this frequency of mutation with that observed in 100 equivalent CA patients. Aim 2: Determine the contribution of AR mutation to PCa heterogeneity in African Americans. Clinical and histopathological heterogeneity of PCa present a major challenge to therapeutic interventions. Differences in AR expression and microvascular density are considered as the two major contributors to PCa heterogeneity. We will use flow cytometry and immunohistochemical staining to examine AR and microvessel density in AA PCa with mutated AR. Aim 3: Define the prognostic significance of AR mutations in primary African American PCa. We will determine the prognostic significance of AR mutations alone or in combination with AR density or microvessel density in relation to clinical or histopathological variables including age, PSA, Gleason score, pathological stage, biochemical recurrence, and family history, with a focus on Gleason sum or pattern as a central prognostic marker. Significance: The results of this exploratory project will provide new knowledge about both the prevalence and prognostic value of AR mutations and may help us to understand better and address more effectively the potential racial disparity between PCa aggressiveness in AAs and CAs. PUBLIC HEALTH RELEVANCE: The incidences, mortality, and aggressiveness of prostate cancer (PCa) in African-American (AA) men are higher than in Caucasians. To understand and address the racial disparity of the disease aggressiveness, reliable prognostic factors are needed. Our discovery of a high frequency of androgen receptor mutations in untreated localized AA PCa might have prognostic significance that would provide us a more effective therapeutic approach.
描述(由申请人提供):非裔美国人(AA)男性的前列腺癌(PCa)发病率和死亡率高于白人美国人(CA)。患有PCa的AA男性也表现出更大的肿瘤体积、更晚期的肿瘤分期和更高的Gleason分级。前列腺癌的发生和发展与雄激素受体(AR)的表达和活性密切相关。AR的突变和基因组扩增也可以增加AR表达和/或活性。在CA中,AR突变在局部肿瘤中很少发生(<1%),但在晚期、转移性或难治性疾病中发生频率较高。在AA中,AR突变的患病率及其在原发性PCa中的预后意义尚不清楚。我们在本实验室建立的一个前列腺癌细胞系中发现了AR的基因组扩增和体细胞突变。我们分析了一组91个根治性直肠癌切除术样本(57个AA和34个CA),其中我们在AA患者中鉴定出8个AR突变(7个体细胞和1个生殖细胞),但在CA患者中没有发现突变。这些数据使我们假设,AR突变在原发性非裔美国人PCa中比预期的更频繁,可能有助于疾病的侵袭性或作为一个预后因素。我们的具体目标是:目标1:确定原发性非裔美国人PCa中AR突变的患病率。将使用AR基因的外显子特异性引物对从根治性前列腺切除术标本的石蜡包埋组织切片的激光捕获细胞中提取的基因组DNA进行测序,以确定400例患有原发性未经治疗的PCa的AA患者中体细胞AR突变的患病率,并将该突变频率与100例等效CA患者中观察到的突变频率进行比较。目的2:确定AR突变对非裔美国人PCa异质性的贡献。PCa的临床和组织病理学异质性是治疗干预的主要挑战。AR表达和微血管密度的差异被认为是PCa异质性的两个主要因素。我们将使用流式细胞术和免疫组织化学染色来检测AR和微血管密度在AA PCa与突变的AR。目的3:确定AR突变在原发性非裔美国人PCa中的预后意义。我们将确定AR突变单独或与AR密度或微血管密度结合与临床或组织病理学变量(包括年龄、PSA、Gleason评分、病理分期、生化复发和家族史)相关的预后意义,重点关注Gleason总和或模式作为中心预后标志物。重要性:这个探索性项目的结果将提供有关AR突变的患病率和预后价值的新知识,并可能帮助我们更好地了解和更有效地解决AA和CA中PCa攻击性之间的潜在种族差异。 公共卫生关系:非裔美国人(AA)男性前列腺癌(PCa)的发病率、死亡率和侵袭性均高于白人。为了了解和解决疾病侵袭性的种族差异,需要可靠的预后因素。我们发现在未经治疗的局部AA PCa中雄激素受体突变的频率很高,这可能具有预后意义,这将为我们提供一种更有效的治疗方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SHAHRIAR KOOCHEKPOUR其他文献

SHAHRIAR KOOCHEKPOUR的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SHAHRIAR KOOCHEKPOUR', 18)}}的其他基金

Therapeutic Efficacy of Riluzole in Prostate Cancer
利鲁唑治疗前列腺癌的疗效
  • 批准号:
    8751365
  • 财政年份:
    2014
  • 资助金额:
    $ 19.98万
  • 项目类别:
Metabotropic Glutamate Receptor 1 in African American Prostate Cancer
非裔美国人前列腺癌中的代谢型谷氨酸受体 1
  • 批准号:
    8675361
  • 财政年份:
    2014
  • 资助金额:
    $ 19.98万
  • 项目类别:
Therapeutic Efficacy of Riluzole in Prostate Cancer
利鲁唑治疗前列腺癌的疗效
  • 批准号:
    8889227
  • 财政年份:
    2014
  • 资助金额:
    $ 19.98万
  • 项目类别:
Metabotropic Glutamate Receptor 1 in African American Prostate Cancer
非裔美国人前列腺癌中的代谢型谷氨酸受体 1
  • 批准号:
    8829801
  • 财政年份:
    2014
  • 资助金额:
    $ 19.98万
  • 项目类别:
PROSAPOSIN, A NOVEL INFLAMMATORY RESPONSE FACTOR FOR PROSTATE CANCER PROGRESSION
PROSAPOSIN,一种前列腺癌进展的新型炎症反应因子
  • 批准号:
    8360448
  • 财政年份:
    2011
  • 资助金额:
    $ 19.98万
  • 项目类别:
Prosaposin: A Novel Biomarker of Prostate Cancer Progression in African Americans
Prosaposin:非裔美国人前列腺癌进展的新型生物标志物
  • 批准号:
    8147010
  • 财政年份:
    2010
  • 资助金额:
    $ 19.98万
  • 项目类别:
Prognostic value of AR mutation in primary African American prostate cancer
AR 突变在非裔美国人原发性前列腺癌中的预后价值
  • 批准号:
    8416144
  • 财政年份:
    2010
  • 资助金额:
    $ 19.98万
  • 项目类别:
Significance of an novel germline AR mutation in black men with prostate cancer
患有前列腺癌的黑人男性中一种新的种系 AR 突变的意义
  • 批准号:
    8367933
  • 财政年份:
    2010
  • 资助金额:
    $ 19.98万
  • 项目类别:
Prosaposin: A Novel Biomarker of Prostate Cancer Progression in African Americans
Prosaposin:非裔美国人前列腺癌进展的新型生物标志物
  • 批准号:
    8391445
  • 财政年份:
    2010
  • 资助金额:
    $ 19.98万
  • 项目类别:
Prosaposin: A Novel Biomarker of Prostate Cancer Progression in African Americans
Prosaposin:非裔美国人前列腺癌进展的新型生物标志物
  • 批准号:
    8501024
  • 财政年份:
    2010
  • 资助金额:
    $ 19.98万
  • 项目类别:

相似海外基金

Broadening Participation Research: Understanding faculty attitudes, competency, and perceptions of providing career advising to African American STEM students at HBCUs
扩大参与研究:了解教师对 HBCU 的非裔美国 STEM 学生提供职业建议的态度、能力和看法
  • 批准号:
    2306671
  • 财政年份:
    2023
  • 资助金额:
    $ 19.98万
  • 项目类别:
    Continuing Grant
Cognitive Behavioral Faith-based Depression Intervention For African American Adults (CB-FAITH): An Effectiveness And Implementation Trial
非裔美国成年人基于认知行为信仰的抑郁干预 (CB-FAITH):有效性和实施试验
  • 批准号:
    10714464
  • 财政年份:
    2023
  • 资助金额:
    $ 19.98万
  • 项目类别:
DELINEATING THE ROLE OF THE HOMOCYSTEINE-FOLATE-THYMIDYLATE SYNTHASE AXIS AND URACIL ACCUMULATION IN AFRICAN AMERICAN PROSTATE TUMORS
描述同型半胱氨酸-叶酸-胸苷酸合成酶轴和尿嘧啶积累在非裔美国人前列腺肿瘤中的作用
  • 批准号:
    10723833
  • 财政年份:
    2023
  • 资助金额:
    $ 19.98万
  • 项目类别:
Exploring PTSD Symptoms, Barriers and Facilitators to Mindfulness-based Stress Reduction for Justice-Involved Black/African American Female Adolescents and Parents/Caregivers
探索创伤后应激障碍 (PTSD) 症状、障碍和促进因素,为涉及正义的黑人/非裔美国女性青少年和父母/照顾者进行基于正念的减压
  • 批准号:
    10593806
  • 财政年份:
    2023
  • 资助金额:
    $ 19.98万
  • 项目类别:
Preventing Firearm Suicide Deaths Among Black/African American Adults
防止黑人/非裔美国成年人因枪支自杀死亡
  • 批准号:
    10811498
  • 财政年份:
    2023
  • 资助金额:
    $ 19.98万
  • 项目类别:
BCSER - PVEST: A Dynamic Framework for Investigating STEM Interest, Attitude and Identity Among African American Middle School Students
BCSER - PVEST:调查非裔美国中学生 STEM 兴趣、态度和身份的动态框架
  • 批准号:
    2327055
  • 财政年份:
    2023
  • 资助金额:
    $ 19.98万
  • 项目类别:
    Standard Grant
Making the Connection: Understanding the dynamic social connections impacting type 2 diabetes management among Black/African American men
建立联系:了解影响黑人/非裔美国男性 2 型糖尿病管理的动态社会联系
  • 批准号:
    10782674
  • 财政年份:
    2023
  • 资助金额:
    $ 19.98万
  • 项目类别:
Building a Community-Based Mental Health Literacy Intervention for African American Young Adults
为非裔美国年轻人建立基于社区的心理健康素养干预措施
  • 批准号:
    10738855
  • 财政年份:
    2023
  • 资助金额:
    $ 19.98万
  • 项目类别:
African American Literature in "post" Post-Racial America
“后”后种族美国中的非裔美国文学
  • 批准号:
    23K00376
  • 财政年份:
    2023
  • 资助金额:
    $ 19.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The Impact of a Race-Based Stress Reduction Intervention on Well-Being, Inflammation, and DNA methylation in Older African American Women at Risk for Cardiometabolic Disease
基于种族的减压干预措施对有心血管代谢疾病风险的老年非洲裔美国女性的健康、炎症和 DNA 甲基化的影响
  • 批准号:
    10633624
  • 财政年份:
    2023
  • 资助金额:
    $ 19.98万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了